Article Text

FRI0258 Improvement of Cell Cholesterol Trafficking-Related Lipoprotein Functions in Rheumatoid Arthritis Patients Treated with Adalimumab
  1. N. Ronda1,
  2. D. Greco1,
  3. M.P. Adorni1,
  4. F. Zimetti1,
  5. E. Favari1,
  6. M.O. Borghi2,
  7. I. Hollan3,
  8. G. Hjeltnes4,
  9. K. Mikkelsen4,
  10. P.L. Meroni5,
  11. F. Bernini1
  1. 1Department of Pharmacy, University of Parma, Parma
  2. 2Dept. of Clinical Sciences and Community Health, University of Milan & IRCCS Istituto Auxologico Italiano, Milan, Italy
  3. 3Lillehammer Hospital for Rheumatic Diseases
  4. 4Dept. of medicine, Innlandet Hospital Trust, Lillehammer, Norway
  5. 5Department of Clinical Sciences and Community Health, University of Milan & Istituto G. Pini & IRCCS Istituto Auxologico Italiano, Milan, Italy


Background RA is associated with accelerated atherosclerosis. HDL in RA have reduced capacity to promote cell cholesterol efflux (CEC) while LDL have increased cholesterol loading capacity on macrophages (CLC). Inflammation and immune disturbances are among the mechanisms proposed. Anti-TNFa agents appear to reduce cardiovascular risk in RA, but their effects on serum lipid profile is variable.

Objectives We studied modifications of lipoprotein function with respect to cell cholesterol trafficking after adalimumab therapy in RA.

Methods Serum was drawn from 56 patients with RA, 34 treated with methotrexate (MTX), 22 starting with adalimumab in addition to ongoing MTX (MTX/ADA), before and after 6 weeks and 6 months of treatment. We measured: serum lipid profile; CLC with cholesterol measurement by fluorimetric technique; CEC with radioisotopic technique.

Results HDL, LDL and total cholesterol serum levels increased in the MTX group after treatment, while HDL levels only increased in the MTX/ADA group. CLC significantly decreased after treatment in the MTX/ADA group only (mean ± SE, 7.16±0.28 vs 7.92±0.48 mg cholesterol/mg protein, p<0.05). In MTX group ATP-binding cassette G1 (ABCG1) and Scavenger receptor-BI (SR-BI)-mediated CEC increased after treatment; in MTX/ADA group SR-BI-mediated CEC increased. No modifications in ATP-binding cassette A1-mediated CEC occurred in either MTX or MTX/ADA group.

Conclusions Adalimumab addition to MTX treatment results in decreased cell cholesterol loading serum capacity and slight improvement in HDL promotion of cell cholesterol efflux, both potentially inhibiting foam cell formation. These effects may be especially relevant in RA patients with aggressive disease needing anti-TNFa, particularly prone to accelerated atherosclerosis.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.2441

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.